Walpar Nutritions reports 16% rise in FY26 consolidated net profit
Walpar Nutritions Limited reported a 16% increase in consolidated net profit to ₹320.70 lakh for FY26, with total revenue rising to ₹7904.97 lakh. The Board approved the audited financial results on May 28, 2026. Standalone net profit grew to ₹196.53 lakh, and revenue from operations reached ₹6529.88 lakh.

*this image is generated using AI for illustrative purposes only.
Walpar Nutritions Limited reported a 16% increase in consolidated net profit to ₹320.70 lakh for the financial year ended March 31, 2026, compared to ₹279.81 lakh in the previous year. The company's total revenue for the year stood at ₹7904.97 lakh, up from ₹7202.93 lakh in FY25. The Board of Directors approved the audited financial results and appointed new auditors at a meeting held on May 28, 2026.
On a standalone basis, the company recorded a net profit of ₹196.53 lakh for FY26, compared to ₹169.26 lakh in the corresponding period of the previous year. Revenue from operations for the standalone entity increased to ₹6529.88 lakh from ₹6016.16 lakh in FY25. The statutory auditors, A Y & Company, issued an unmodified opinion on the financial results.
Consolidated Financial Performance
The consolidated financial results include the performance of subsidiaries Walpar Wellness Private Limited and Walpar Nutri Science Private Limited, as well as associate company Pallota Nutritions Private Limited. Profit attributable to the owners of the parent rose to ₹247.44 lakh for the year ended March 31, 2026, from ₹232.44 lakh in the prior year.
| Metric | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|
| Total Revenue | 7904.97 | 7202.93 |
| Total Expenses | 7494.66 | 6815.14 |
| Profit Before Tax | 410.31 | 387.79 |
| Net Profit | 320.70 | 279.81 |
| Earnings Per Share (Basic) | 2.64 | 2.48 |
Assets and Liabilities
The consolidated total assets as of March 31, 2026, stood at ₹6607.20 lakh, an increase from ₹4738.65 lakh in the previous year. Shareholders' funds grew to ₹1890.00 lakh, comprising share capital of ₹939.04 lakh and reserves of ₹950.96 lakh. The company reported no outstanding defaults on loans or debt securities as of the reporting date.
Segment Reporting
The company operates in a single primary segment focused on the manufacturing and trading of pharmaceutical, nutraceutical, herbal, and Ayurvedic commodities. Consequently, segment-wise reporting in accordance with Accounting Standard 17 is not applicable. There were no investor complaints pending as of March 31, 2026.
Historical Stock Returns for Walpar Nutritions
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.92% | -9.24% | -19.05% | -27.39% | -38.56% | -47.46% |
What strategic initiatives will Walpar Nutritions pursue to sustain the double-digit revenue growth observed in FY26?
How does the company plan to utilize the significant increase in consolidated total assets to drive future expansion?
Will the company consider declaring dividends in the upcoming fiscal year given the growth in shareholders' funds and net profit?


























